In comparison to the control group, anti-CTLA-4 treatment significantly increased the percentage of tumor-infiltrating CD8+ T-cells (Fig. 3c), and decreased tumor-infiltrating Tregs (Fig. 3e), with a consequent increased ratio of CD8+ T-cells to Tregs (Fig. 3f). Here, CTLA4 is linked to neoplasm.